ExonHit licenses Merck rights to RNA splicing microarray patent

ExonHit Therapeutics S.A., a drug and diagnostic discovery company, has announced that Merck & Co., Inc. has been granted a non-exclusive license to rights for research only under Patent US 6,881,571.

It is not anticipated that the revenues received by ExonHit from Merck under this agreement will exceed US$150,000 per year.

Patent US 6,881,571, entitled "Qualitative Differential Screening", was granted on April 19, 2005 and has claims directed to microarrays optimized for the monitoring of RNA splicing events.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
VAX-seq: the future of mRNA vaccine analysis and quality assurance?